Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
ConditionMalignant Neoplasm
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMerck Sharp & Dohme LLC
About this trial
Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors.
The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
Eligibility criteria
Qualifiers
Colorectal carcinoma (CRC)
Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoid and/or rhabdoid features)
Nonsquamous non-small cell lung cancer (NSCLC)
Biliary tract cancer (BTC) (intra-or extrahepatic cholangiocarcinoma (CCA)) or gallbladder cancer (GBC)
Disqualifiers
Has gastrointestinal malabsorption, a surgical procedure or a condition that could affect the absorption of the study drug
Has a history of clinically significant cardiac, cardiovascular and/or cerebrovascular disease
Has a serious nonhealing wound, ulcer, or bone fracture
Has an active infection(s) requiring systemic therapy
Trial design
Treatments tested in this trial
- MK-4884
Treatment groups
120 Participants
are divided into 2 treatment groupsLocations
4Israel
Rambam Health Care Campus ( Site 0051)3109601, Haifa Israel
Rabin Medical Center ( Site 0053)4941492, Petah Tikva Israel
Japan
National Cancer Center Hospital ( Site 0201)104-0045, ChūōTokyo, Japan
United States
NEXT Oncology ( Site 0151)78229, San AntonioTexas, United States
Sponsors and collaborators
Merck Sharp & Dohme LLC
Lead sponsor
Source ClinicalTrials.gov